Skip to main content
Fig. 1 | Molecular Cancer

Fig. 1

From: Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers

Fig. 1

Serial molecular profiling by liquid biopsy and pharmacogenomics across various phases of lung cancer such as screening, treatment planning, monitoring of pharmacotherapy till remission free stage for precision therapy of EGFR mutant and resistant lung cancer. Created with BioRender.com (Agreement number: FS237SI0R8). Abbreviations: EGFR: Epidermal growth factor receptor; TKIs: Tyrosine kinase inhibitors; PGx: Pharmacogenomics; TDM: Therapeutic drug monitoring

Back to article page

Molecular Cancer

ISSN: 1476-4598